These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28834859)

  • 1. Novel Psychoactive Substances and Trends of Abuse.
    Rivera JV; Vance EG; Rushton WF; Arnold JK
    Crit Care Nurs Q; 2017; 40(4):374-382. PubMed ID: 28834859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicology and management of novel psychoactive drugs.
    Kersten BP; McLaughlin ME
    J Pharm Pract; 2015 Feb; 28(1):50-65. PubMed ID: 25261428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel psychoactive substances: What educators need to know.
    Patterson ZR; Young MM; Vaccarino FJ
    Clin Pharmacol Ther; 2017 Feb; 101(2):173-175. PubMed ID: 27756105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New and Emerging Illicit Psychoactive Substances.
    Graddy R; Buresh ME; Rastegar DA
    Med Clin North Am; 2018 Jul; 102(4):697-714. PubMed ID: 29933824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study.
    Hill SL; Najafi J; Dunn M; Acheampong P; Kamour A; Grundlingh J; Blain PG; Thomas SH
    Clin Toxicol (Phila); 2016 Sep; 54(8):638-43. PubMed ID: 27251903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4,4'-DMAR: chemistry, pharmacology and toxicology of a new synthetic stimulant of abuse.
    Coppola M; Mondola R
    Basic Clin Pharmacol Toxicol; 2015 Jul; 117(1):26-30. PubMed ID: 25819702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the activity and toxicity of new psychoactive substances: a pharmaceutical industry perspective.
    Leach AG
    Drug Test Anal; 2014; 6(7-8):739-45. PubMed ID: 24353222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New psychoactive substances: a public health issue.
    Guirguis A
    Int J Pharm Pract; 2017 Oct; 25(5):323-325. PubMed ID: 28895252
    [No Abstract]   [Full Text] [Related]  

  • 9. Identification of novel psychoactive drug use in Sweden based on laboratory analysis--initial experiences from the STRIDA project.
    Helander A; Beck O; Hägerkvist R; Hultén P
    Scand J Clin Lab Invest; 2013 Aug; 73(5):400-6. PubMed ID: 23692208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An index of fatal toxicity for new psychoactive substances.
    King LA; Corkery JM
    J Psychopharmacol; 2018 Jul; 32(7):793-801. PubMed ID: 29482434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of Acute Toxicity Associated with New Psychoactive Substances.
    Hill SL; Dargan PI
    Handb Exp Pharmacol; 2018; 252():475-494. PubMed ID: 29896654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the risks associated with the use of new psychoactive substances (NPS): high variability of active ingredients concentration, mislabelled preparations, multiple psychoactive substances in single products.
    Zamengo L; Frison G; Bettin C; Sciarrone R
    Toxicol Lett; 2014 Aug; 229(1):220-8. PubMed ID: 24910986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New psychoactive substances: an overview on recent publications on their toxicodynamics and toxicokinetics.
    Meyer MR
    Arch Toxicol; 2016 Oct; 90(10):2421-44. PubMed ID: 27665567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the toxicological significance of new psychoactive substances in fatalities.
    Elliott S; Sedefov R; Evans-Brown M
    Drug Test Anal; 2018 Jan; 10(1):120-126. PubMed ID: 28635164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel psychoactive substances.
    Krabseth HM; Tuv SS; Strand MC; Karinen RA; Wiik E; Vevelstad MS; Westin AA; Øiestad EL; Vindenes V
    Tidsskr Nor Laegeforen; 2016 May; 136(8):714-7. PubMed ID: 27143461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.
    Chung EY; Cha HJ; Min HK; Yun J
    Arch Pharm Res; 2021 Apr; 44(4):402-413. PubMed ID: 33811300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profile, effects, and toxicity of novel psychoactive substances: A systematic review of quantitative studies.
    Assi S; Gulyamova N; Ibrahim K; Kneller P; Osselton D
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28631432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next generation of novel psychoactive substances on the horizon - A complex problem to face.
    Zawilska JB; Andrzejczak D
    Drug Alcohol Depend; 2015 Dec; 157():1-17. PubMed ID: 26482089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using poisons information service data to assess the acute harms associated with novel psychoactive substances.
    Wood DM; Hill SL; Thomas SH; Dargan PI
    Drug Test Anal; 2014; 6(7-8):850-60. PubMed ID: 24832864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015.
    Mounteney J; Griffiths P; Sedefov R; Noor A; Vicente J; Simon R
    Addiction; 2016 Jan; 111(1):34-48. PubMed ID: 26419329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.